Pharmaceutical News

RSS

Heart risk warning wanted on ADHD drugs

A U.S. advisory panel has recommended that drugs used by millions to treat attention deficit hyperactivity disorder (ADHD), should carry a warning of the risk of heart problems.

12 Feb 2006

Sanofi pasteur delivers more H5N1 vaccines to U.S. Government

Sanofi pasteur has delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant.

7 Feb 2006

FDA grants fast track status for ViroPharma's Maribavir

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for maribavir, an oral antiviral drug candidate for the prevention of cytomegalovirus (CMV) infection in allogeneic bone marrow (stem cell) and solid organ transplant patients.

7 Feb 2006

Viragen reports on Multiferon anti-viral studies

Viragen, Inc today reported on the progression of anti-viral studies using Multiferon (multi-subtype, natural human alpha interferon) being conducted by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

7 Feb 2006

Bristol-Myers Squibb and Otsuka Pharmaceutical announce availability of 2 mg Abilify (aripiprazole) tablet

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced two newly available options of Abilify (aripiprazole) -- a 2 mg tablet strength and a nonrefrigerated oral solution (1 mg/mL).

7 Feb 2006

Monotherapy phase I clinical trials of novel cytotoxics, targeted therapeutics, antimetastatic agents/angiogenesis inhibitors, and immunotherapeutics/vaccines

Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)

7 Feb 2006

Angina drug finally gets the ok

U.S. regulators have granted approval for the drug Ranexa in the treatment of chronic angina.

31 Jan 2006

Postcode decides whether women receive breast cancer drug Herceptin

A British woman is so desperate to be given access to the breast cancer drug Herceptin that she is prepared to protest at the government's Welsh assembly in the Welsh capital Cardiff.

30 Jan 2006

New inhaled drug for diabetics an alternative treatment option for some

The Food and Drug Administration (FDA) in the U.S. has given it's approval for the sale of a new drug to treat diabetes.

29 Jan 2006

Aston Academy investigates macular oedema

Aston Academy of Life Sciences, the clinical research hospital of Aston University, has recently been commissioned to assess the efficacy and safety of a specialist drug, Posurdex (Allergan Ltd, UK), which is used in the treatment of patients who suffer from a sight threatening condition, called macular oedema.

26 Jan 2006

FDA wants asthma drug withdrawn

An FDA advisory panel has advised that an over-the-conter (OTC) asthma drug should be withdrawn.

26 Jan 2006

Drug used worldwide doubles risk of kidney failure

A drug approved by the FDA, and sold worldwide for the last 13 years, has now been proven to double a patient's risk of kidney failure, and increase the risk of heart attack, heart failure, and stroke.

26 Jan 2006

Student doctors call for ban on drug company bribes

Medical students in the U.S. are applauding a study published in the Journal of the American Medical Association (JAMA), which calls for a ban on gifts to doctors from drug companies.

26 Jan 2006

FDA panel gives weight-loss drug the thumbs up

An FDA advisory panel has declared that an over-the-counter weight-loss drug appears to be safe and effective for a six month period of use.

24 Jan 2006

Concern over decision that new Alzheimer drugs only available for advanced disease

The recommendation by the National Institute of Clinical Evidence (NICE), that Alzheimer's drugs should be used in a minority of people with the degenerative brain disease, has created both rage and disbelief from charities and drug companies alike.

24 Jan 2006

French defend drug after patients develop liver problems

Health authorities in the U.S. are recommending that doctors keep a close eye on patients taking Ketek for signs of liver problems and to stop treatment if symptoms develop.

24 Jan 2006

Injection of EU funds for a microdose project

A new EU-funded project kicked off this month which aims to bridge the gap between the laboratory and the clinic. The EU Microdose AMS Partnership Programme (EUMAPP) aims to boost Europe’s expertise in micodosing and its application of AMS, or accelerator mass spectrometry, to developing new candidate drugs for treating diseases the world over.

23 Jan 2006

Statins account for 81% of first-line therapies for dyslipidemia treatment

Decision Resources, Inc., finds that despite the dominant market position of statins in the treatment of dyslipidemia, only 81% of patients receive a statin as a first-line therapy for the disease.

23 Jan 2006

Bristol-Myers Squibb agrees to record securities litigation settlement with sweeping drug disclosure requirements announces Labaton Sucharow

After prosecuting the securities litigation claims against Bristol-Myers Squibb Co. (BMS) for over five years, Labaton Sucharow, Lead Counsel representing the class and Lead Plaintiff, the LongView Collective Investment Fund of the Amalgamated Bank, reached an agreement in principle to settle the claims for $185 million in addition to meaningful corporate governance reforms that will affect future consumers and investors alike.

23 Jan 2006

American Academy of Dermatology disagrees with eczema medication action taken by FDA

The American Academy of Dermatology (Academy) has issued a statement in response to the U.S. Food and Drug Administration’s (FDA) announcement that a black box warning will be added to the labeling and a medication guide will be distributed for the topical calcineurin inhibitors (TCIs), pimecrolimus and tacrolimus.

23 Jan 2006